Impact of Sequential Ramucirumab Plus Docetaxel After PD ‐1 Inhibitors on Anti‐ PD ‐1 Antibody‐Bound T‐Cell Dynamics and Clinical Outcomes
Open Access
- 30 January 2026
- journal article
- Published by Wiley in Cancer Science
- Vol. 117 (4) , 929-942
Abstract
Ramucirumab plus docetaxel (RAM+DOC) demonstrates clinical activity after programmed cell death‐1 (PD‐1) inhibitors in advanced non‐small cell lung cancer (NSCLC); however, the underlying mechanisms remain unclear. We aimed to evaluate clinical efficacy and explore immunologic dynamics and benefit‐associated biomarkers. Patients treated with RAM+DOC after PD‐1 inhibitors were enrolled in a multicenter prospective cohort. Anti‐PD‐1 antibody bound (IgG4 + ) T‐cell subsets were measured at baseline (T0) and after 2–3 cycles (T1), reflecting residual anti‐PD‐1 antibody binding on circulating T cells. T1/T0 ratios of immune subsets were calculated to assess dynamics. Landmark analyses at T1 evaluated associations with progression‐free survival (PFS) and overall survival (OS). Prognostic biomarkers were assessed at baseline. Among 27 evaluable patients, the objective response rate was 37.0%, median PFS 5.1 months, and OS 10.4 months. RAM + DOC responders had higher IgG4 + CD8 + T‐cell and lower IgG4 + Treg T1/T0 ratios (both p < 0.001). Higher IgG4 + CD8 + ratios were associated with longer landmark PFS ( p = 0.002) and OS ( p = 0.016) and were inversely correlated with IgG4 + Treg ratios ( p = 0.008). Among the baseline factors, high IgG4 + CD8 + Temra conferred survival benefits (OS, not reached vs. 8.2 months; p = 0.006), and low vascular endothelial growth factor (VEGF)‐C levels were associated with longer OS (not reached vs. 8.5 months, p = 0.044). Both variables remained independent prognostic factors of PFS and OS in multivariable analysis. Our findings suggest that sequential strategy administering RAM+DOC during persistent binding of anti–PD‐1 antibody to T cells may be beneficial. IgG4 + CD8 + Temra and VEGF‐C levels at RAM+DOC initiation may serve as biomarkers of survival benefit. Trial Registration: UMIN‐Clinical Trials Registry (UMIN000050478)Keywords
Funding Information
- Ministry of Education, Culture, Sports, Science and Technology (JPMXP1323015484)
- Japan Society for the Promotion of Science (20H05698)
- Japan Agency for Medical Research and Development (25ama221533h0002)
- Eli Lilly Japan
- Japan Science and Technology Agency (JPMJSP2138)
- Support for Pioneering Research Initiated by the Next Generation
This publication has 42 references indexed in Scilit:
- Design of a fragment crystallizable-engineered tetravalent bispecific antibody targeting programmed cell death-1 and vascular endothelial growth factor with cooperative biological effectsiScience, 2024
- Five-year outcomes with first-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus 4 cycles of chemotherapy alone in patients with metastatic non-small cell lung cancer in the randomized CheckMate 9LA trialEuropean Journal of Cancer, 2024
- Efficacy and safety of second-line therapy of docetaxel plus ramucirumab after first-line platinum-based chemotherapy plus immune checkpoint inhibitors in non-small cell lung cancer (SCORPION): a multicenter, open-label, single-arm, phase 2 trialeClinicalMedicine, 2023
- AK112, a novel PD-1/VEGF bispecific antibody, in combination with chemotherapy in patients with advanced non-small cell lung cancer (NSCLC): an open-label, multicenter, phase II trialeClinicalMedicine, 2023
- Multicentre real-world data of ramucirumab plus docetaxel after combined platinum-based chemotherapy with programmed death-1 blockade in advanced non-small cell lung cancer: NEJ051 (REACTIVE study)European Journal of Cancer, 2023
- Impact of treatment timing and sequence of immune checkpoint inhibitors and anti-angiogenic agents for advanced non-small cell lung cancer: A systematic review and meta-analysisLung Cancer, 2021
- Biomarker analyses of second-line ramucirumab in patients with advanced gastric cancer from RAINBOW, a global, randomized, double-blind, phase 3 studyEuropean Journal of Cancer, 2020
- VEGF-C in non-small cell lung cancer: Meta-analysisClinica Chimica Acta, 2014
- VEGFR2 is selectively expressed by FOXP3high CD4+ TregEuropean Journal of Immunology, 2009
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009